Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Investors Are Buzzing About Apple, Ford, Teva, Mylan, and Southwest Airlines This Morning

Page 1 of 2

After Friday’s sharp drop in equity prices, more investors are keeping tabs on the market to see whether the recent interest rate fears will cause the indexes to enter into correction territory. Although the market is nowhere close to correction levels currently, stocks have historically fallen faster than they rise. Whether stocks will be a good buy in the short-to-medium terms is an open question.

Among the stocks that are capturing traders’ interest today are Mylan NV (NASDAQ:MYL), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Ford Motor Company (NYSE:F), Apple Inc. (NASDAQ:AAPL), and Southwest Airlines Co (NYSE:LUV). In this article, we’ll examine the events that are garnering attention for each stock while also using the latest 13F filings data to see how successful hedge funds are positioned in them.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Best Selling Smartphones in Japan

Mylan NV (NASDAQ:MYL)‘s EpiPen might get competition sooner than expected. Although Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘s generic application for an EpiPen-like product was rejected by the FDA in February due to “major deficiencies”, it seems the recent political controversy over Mylan’s past price increases in the essential drug has prompted the FDA to change its mind. According to Teva, due to the “media attention in the last two weeks, the FDA has come back to us and we will have a meeting very, very quickly.” Given the FDA’s sudden shift, Teva says that it now hopes to win the agency’s approval for a generic version of the treatment by late-2017 or early-2018. If that happens, Mylan’s EpiPen market-share, which currently stands at around 94%, could fall dramatically. That’s important news for Mylan, as EpiPen accounted for about one-fifth of the drug company’s profits before it was forced to cut pricing by 50% in many cases.

Follow Mylan Inc. (NASDAQ:MYL)
Trade (NASDAQ:MYL) Now!

Of the 749 hedge funds that we track which filed 13Fs for the June quarter, 44 owned shares of Mylan NV (NASDAQ:MYL) on June 30 and 55 had a long position in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).

Follow Teva Pharmaceutical Inds Ltd (NYSE:TEVA)
Trade (NYSE:TEVA) Now!

Southwest Airlines Co (NYSE:LUV) is in the news after the company reached a deal in principle with the Transport Workers Union, which represents around 12,000 flight attendants. Although the terms of the tentative deal were not released, more certainty is always good. A labor strike would have severely hurt Southwest’s business and near-term profits. Southwest previously struck a tentative deal with its pilots union in August. David Tepper‘s Appaloosa Management established a new stake of almost 3.5 million shares in Southwest Airlines Co (NYSE:LUV) in the second quarter.

Follow Southwest Airlines Co (NYSE:LUV)
Trade (NYSE:LUV) Now!

On the next page, we’ll examine the headline-making events concerning Ford and Apple over the weekend.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!